Defining the role of macrophages in local moxifloxacin tissue concentrations using biopsy data and Whole-body physiologically based pharmacokinetic modelling

Clinical Pharmacokinetics

Volumn 48, Issue 3, 2009, Pages 181-187

  Edginton, Andrea N ^a   Ahr, Gertrud ^b   Willmann, Stefan ^a   Stass, Heino ^b  

^a BAYER AG   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN;

ARTICLE; BIOPSY; CLINICAL ARTICLE; COLORECTAL SURGERY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTERSTITIUM; MACROPHAGE; MICRODIALYSIS; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; AZA COMPOUNDS; BIOPSY; COLORECTAL NEOPLASMS; HALF-LIFE; HUMANS; MACROPHAGES; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PROTEIN BINDING; QUINOLINES; TISSUE DISTRIBUTION;

EID: 65349179649     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200948030-00004     Document Type: Article

References (36)

1. Liu P, Muller M, Grant M, et al. Tissue penetration of cefpodoxime and cefixime in healthy subjects. J Clin Pharmacol 2005; 45 (5): 564-9
2. Gattringer R, Urbauer E, Traunmuller F, et al. Pharmacokinetics of telithromycin in plasma and soft tissues after single-dose administration to healthy volunteers. Antimicrob Agents Chemother 2004; 48 (12): 4650-3
3. Skhirtladze K, Hutschala D, Fleck T, et al. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob Agents Chemother 2006; 50 (4): 1372-5
4. Ludbrook GL, Visco E, Lam AM. Propofol: relation between brain concentrations, electroencephalogram, middle cerebral artery blood flow velocity, and cerebral oxygen extraction during induction of anesthesia. Anesthesiology 2002; 97 (6): 1363-70
5. Sauermann R, le-Karth G, Marsik C, et al. Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients. Antimicrob Agents Chemother 2005; 49 (2): 650-5
6. Bellmann R, Kuchling G, Dehghanyar P, et al. Tissue pharmacokinetics of levofloxacin in human soft tissue infections. Br J Clin Pharmacol 2004; 57 (5): 563-8
7. Joukhadar C, Frossard M, Mayer BX, et al. Impaired target site penetration of beta-lactamsmay account for therapeutic failure in patients with septic shock. Crit Care Med 2001; 29 (2): 385-91
8. Joukhadar C, MullerM.Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future. Clin Pharmacokinet 2005; 44 (9): 895-913
9. Muller M. Microdialysis in clinical drug delivery studies. Adv Drug Deliv Rev 2000; 45 (2-3): 255-69
10. Stass H, Kubitza D, Moller JG, et al. Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males. Br J Clin Pharmacol 2005; 59 (5): 536-41
11. Stass H. Distribution and tissue distribution of moxifloxacin. Drugs 1999; 58 Suppl. 2: 229-30
12. Pascual A, Garcia I, Ballesta S, et al. Uptake and intracellular activity of moxifloxacin in human neutrophils and tissue-cultured epithelial cells. Antimicrob Agents Chemother 1999; 43 (1): 12-5
13. Soman A, Honeybourne D, Andrews J, et al. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1999; 44 (6): 835-8
14. Seral C, Barcia-Macay M, Mingeot-Leclercq MP, et al. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages. J Antimicrob Chemother 2005; 55 (4): 511-7
15. Mandell GL, Coleman E. Uptake, transport, and delivery of antimicrobial agents by human polymorphonuclear neutrophils. Antimicrob Agents Chemother 2001; 45 (6): 1794-8
16. Wirtz M, Kleeff J, Swoboda S, et al. Moxifloxacin penetration into human gastrointestinal tissues. J Antimicrob Chemother 2006; 53: 875-7
17. Edginton AN, Willmann S, Schmitt W. Development and evaluation of a generic physiology-based pharmacokinetic (PBPK) model for children. Clin Pharmacokinet 2006; 45 (10): 1013-34
18. Willmann S, Lippert J, Schmitt W. From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools. Expert Opin Drug Meta Toxicol 2005; 1 (1): 159-68
19. Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies: 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 2001; 91 (1): 129-56
20. DeJongh J, Verhaar HJ, Hermens JL. A quantitative property-property relationship (QPPR) approach to estimate in vitro tissue-blood partition coefficients of organic chemicals in rats and humans. Arch Toxicol 1997; 72 (1): 17-25
21. International Commission on Radiological Protection (ICRP). Basic anatomical and physiological data for use in radiological protection: reference values. ICRP publication no. 89. Amsterdam: Elsevier Science, 2002
22. von Kleist M, Huisinga W. Physiologically based pharmacokinetic modelling: a sub-compartmentalized model of tissue distribution. J Pharmacokinet Pharmacodyn 2007; 34 (6): 789-806
23. Muller M, Stass H, Brunner M, et al. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob Agents Chemother 1999; 43 (10): 2345-9
24. Joukhadar C, Stass H, Muller-Zellenberg U, et al. Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans. Antimicrob Agents Chemother 2003; 47 (10): 3099-103
25. Willmann S, Lippert J, Sevestre M, et al. PK-Sim-: a physiologically based pharmacokinetic 'whole-body' model. Biosilico 2003; 1 (4): 121-4
26. Willmann S, Hohn K, Edginton A, et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn 2007; 34 (3): 401-31
27. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9 (4): 503-12
28. Etoh T, Shibuta K, Barnard GF, et al. Angiogenin expression in human colorectal cancer: the role of focal macrophage infiltration. Clin Cancer Res 2000; 6 (9): 3545-51
29. Garraffo R, Jambou D, Chichmanian RM, et al. In vitro and in vivo ciprofloxacin pharmacokinetics in human neutrophils. Antimicrob Agents Chemother 1991; 35 (11): 2215-8
30. Isbel NM, Nikolic-Paterson DJ,Hill PA, et al. Local macrophage proliferation correlates with increased renal M-CSF expression in human glomerulonephritis. Nephrol Dial Transplant 2001; 16 (8): 1638-47
31. Barcia-Macay M, Seral C, Mingeot-Leclercq MP, et al. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother 2006; 50 (3): 841-51
32. Nguyen HA, Grellet J, Paillard D, et al. Factors influencing the intracellular activity of fluoroquinolones: a study using levofloxacin in a Staphylococcus aureus THP-1 monocyte model. J Antimicrob Chemother 2006; 57 (5): 883-90
33. Michot JM, Heremans MF, Caceres NE, et al. Cellular accumulation and activity of quinolones in ciprofloxacin-resistant J774 macrophages. Antimicrob Agents Chemother 2006; 50 (5): 1689-95
34. Garraffo R, Roptin C, Boudjadja A. Impact of neutropenia of tissue penetration of moxifloxacin and sparfloxacin in infected mice. Drugs 1999; 68 Suppl. 2: 242-5
35. Maschmeyer G, Haralambie E, Gaus W, et al. Ciprofloxacin and norfloxacin for selective decontamination in patients with severe granulocytopenia. Infection 1988; 16 (2): 98-104
36. Wilms EB, Touw DJ, Heijerman HGM. Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during longterm therapy in patients with cystic fibrosis. Ther Drug Monitor 2006; 28 (2): 219-25